
IDXX
IDEXX Laboratories Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
520.000
Open
519.020
VWAP
515.90
Vol
130.28K
Mkt Cap
41.68B
Low
510.160
Amount
67.21M
EV/EBITDA(TTM)
33.31
Total Shares
82.59M
EV
42.63B
EV/OCF(TTM)
44.03
P/S(TTM)
10.87
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.03B
+8.2%
2.868
+9.45%
1.05B
+7.16%
3.096
+10.57%
1.06B
+5.73%
3.268
+8.21%
Estimates Revision
The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by 17.55%.
Revenue Estimates for FY2025
Revise Upward

+0.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+1.67%
In Past 3 Month
Stock Price
Go Up

+17.55%
In Past 3 Month
7 Analyst Rating

-0.98% Downside
Wall Street analysts forecast IDXX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 508.83 USD with a low forecast of 460.00 USD and a high forecast of 548.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy

-0.98% Downside
Current: 513.875

Low
460.00
Averages
508.83
High
548.00

-0.98% Downside
Current: 513.875

Low
460.00
Averages
508.83
High
548.00
Stifel
Jonathan Block
Hold
Maintains
$460 → $510
2025-05-19
Reason
Stifel
Jonathan Block
Price Target
$460 → $510
2025-05-19
Maintains
Hold
Reason
Stifel
Jonathan Block
Hold
Maintains
$450 → $420
2025-04-14
Reason
Stifel
Jonathan Block
Price Target
$450 → $420
2025-04-14
Maintains
Hold
Reason
Piper Sandler
David Westenberg
Hold
Maintains
$435 → $510
2025-02-10
Reason
Piper Sandler
David Westenberg
Price Target
$435 → $510
2025-02-10
Maintains
Hold
Reason
Piper Sandler raised the firm's price target on Idexx Laboratories to $510 from $435 and keeps a Neutral rating on the shares. The firm cites updated estimates and moving forward of its estimate year to 2026 from 2025.
B of A Securities
Michael Ryskin
Hold
Maintains
$475 → $535
2025-02-04
Reason
B of A Securities
Michael Ryskin
Price Target
$475 → $535
2025-02-04
Maintains
Hold
Reason
Barclays
Balaji Prasad
Buy
Maintains
$481 → $520
2025-02-04
Reason
Barclays
Balaji Prasad
Price Target
$481 → $520
2025-02-04
Maintains
Buy
Reason
Morgan Stanley
Erin Wright
Buy
Maintains
$559 → $550
2025-01-29
Reason
Morgan Stanley
Erin Wright
Price Target
$559 → $550
2025-01-29
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 41.39, compared to its 5-year average forward P/E of 52.28. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
52.28
Current PE
41.39
Overvalued PE
64.80
Undervalued PE
39.77
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
36.39
Current EV/EBITDA
29.44
Overvalued EV/EBITDA
44.91
Undervalued EV/EBITDA
27.87
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
11.36
Current PS
9.89
Overvalued PS
13.85
Undervalued PS
8.88
Financials
Annual
Quarterly
FY2025Q1
YoY :
+3.56%
998.43M
Total Revenue
FY2025Q1
YoY :
+5.88%
316.53M
Operating Profit
FY2025Q1
YoY :
+3.01%
242.68M
Net Income after Tax
FY2025Q1
YoY :
+5.34%
2.96
EPS - Diluted
FY2025Q1
YoY :
+23.54%
207.94M
Free Cash Flow
FY2025Q1
YoY :
+1.50%
62.44
Gross Profit Margin - %
FY2025Q1
YoY :
-0.37%
21.31
FCF Margin - %
FY2025Q1
YoY :
-0.53%
24.31
Net Margin - %
FY2025Q1
YoY :
-4.53%
37.51
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.2M
USD
4
3-6
Months
6.0M
USD
2
6-9
Months
379.3K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
59.5K
Volume
8
6-9
Months
0.0
Volume
0
0-12
Months
132.0K
Volume
12
Bought
0-3
0
0.0
Volume
Months
3-6
12
78.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
25
339.8K
Volume
Months
Congress Trading
Congress areBuying! The buying amount has increased164.2%over the last month.
Sold
0-3
Months
16.0K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
14
295.0K
USD
Months
3-6
1
8.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.2M
USD
4
3-6
Months
6.0M
USD
2
6-9
Months
379.3K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IDXX News & Events
Events Timeline
2025-05-01 (ET)
2025-05-01
09:55:01
Early notable gainers among liquid option names on May 1st

2025-05-01
07:11:41
Idexx Laboratories raises 2025 EPS view 19c to $11.93-$12.43, consensus $11.99

2025-05-01
07:10:05
Idexx Laboratories reports Q1 EPS $2.96, consensus $2.84

Sign Up For More Events
Sign Up For More Events
News
6.5
00:01 AMCNBCCramer's Lightning Round: Leidos is a buy
5.0
05-19NASDAQ.COMHere are the Top Stocks That Congress has Been Buying Lately
3.0
05-19NASDAQ.COMValidea Detailed Fundamental Analysis - IDXX
Sign Up For More News
People Also Watch

PM
Philip Morris International Inc
176.490
USD
-1.29%

ISRG
Intuitive Surgical Inc
555.980
USD
+0.65%

LCID
Lucid Group Inc
2.385
USD
-9.32%

ZS
Zscaler Inc
253.090
USD
-0.22%

COF
Capital One Financial Corp
190.430
USD
-0.34%

NVS
Novartis AG
112.130
USD
+0.23%

SHEL
Shell PLC
66.160
USD
+0.18%

ERIC
Telefonaktiebolaget LM Ericsson
8.520
USD
-0.23%

LIN
Linde PLC
463.700
USD
+0.26%

ABT
Abbott Laboratories
132.310
USD
+0.22%
FAQ

What is IDEXX Laboratories Inc (IDXX) stock price today?
The current price of IDXX is 513.875 USD — it has decreased -0.09 % in the last trading day.

What is IDEXX Laboratories Inc (IDXX)'s business?

What is the price predicton of IDXX Stock?

What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?

What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for IDEXX Laboratories Inc (IDXX)'s fundamentals?

How many employees does IDEXX Laboratories Inc (IDXX). have?
